These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 32394765)
1. Switching biologics in psoriasis - practical guidance and evidence to support. Tsai YC; Tsai TF Expert Rev Clin Pharmacol; 2020 May; 13(5):493-503. PubMed ID: 32394765 [TBL] [Abstract][Full Text] [Related]
2. Biologics in pediatric psoriasis - efficacy and safety. Dogra S; Mahajan R Expert Opin Drug Saf; 2018 Jan; 17(1):9-16. PubMed ID: 29022425 [TBL] [Abstract][Full Text] [Related]
3. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226 [TBL] [Abstract][Full Text] [Related]
4. Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis. Hsu SH; Tsai TF Expert Rev Clin Pharmacol; 2020 Mar; 13(3):211-232. PubMed ID: 32167790 [No Abstract] [Full Text] [Related]
5. Sequencing of Targeted Therapy in Psoriasis: Does it Matter? Boswell ND; Singla S; Gordon KB Am J Clin Dermatol; 2024 Sep; 25(5):795-810. PubMed ID: 39003351 [TBL] [Abstract][Full Text] [Related]
6. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis. Hu Y; Chen Z; Gong Y; Shi Y Clin Drug Investig; 2018 Mar; 38(3):191-199. PubMed ID: 29249053 [TBL] [Abstract][Full Text] [Related]
7. Biologics in the treatment of pustular psoriasis. Wang WM; Jin HZ Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817 [TBL] [Abstract][Full Text] [Related]
8. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071 [No Abstract] [Full Text] [Related]
9. Real-world outcome analysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent. Hjalte F; Steen Carlsson K; Schmitt-Egenolf M Dermatology; 2015; 230(4):347-53. PubMed ID: 25721571 [TBL] [Abstract][Full Text] [Related]
10. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. Curmin R; Guillo S; De Rycke Y; Bachelez H; Beylot-Barry M; Beneton N; Chosidow O; Dupuy A; Joly P; Jullien D; Richard MA; Viguier M; Sbidian E; Paul C; Mahé E; Tubach F; J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2101-2112. PubMed ID: 35793473 [TBL] [Abstract][Full Text] [Related]
11. Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience. Özkur E; Kıvanç Altunay İ; Oğuz Topal İ; Aytekin S; Topaloğlu Demir F; Özkök Akbulut T; Kara Polat A; Karadağ AS Dermatology; 2021; 237(1):22-30. PubMed ID: 31865339 [TBL] [Abstract][Full Text] [Related]
12. Switching of biologics in psoriasis: Reasons and results. Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283 [TBL] [Abstract][Full Text] [Related]
13. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130 [TBL] [Abstract][Full Text] [Related]
14. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data. Kolli SS; Kepley AL; Cline A; Feldman SR Expert Opin Drug Saf; 2019 Jun; 18(6):523-536. PubMed ID: 31046481 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018 [TBL] [Abstract][Full Text] [Related]
17. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Al-Mutairi N; Nour T Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040 [TBL] [Abstract][Full Text] [Related]
18. Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea. Shin JO; Shin BS; Bae KN; Shin K; Kim HS; Ko HC; Kim MB; Kim B Indian J Dermatol Venereol Leprol; 2023; 89(6):928. PubMed ID: 37317715 [TBL] [Abstract][Full Text] [Related]
19. Switching from a biological therapy to another biologic agent in psoriatic patients: the experience of PsOMarche group. Ganzetti G; Campanati A; Bettacchi A; Brandozzi G; Brisigotti V; Bugatti L; Cataldi I; Filosa G; Giacchetti A; Lemme G; Morresi L; Nicolini M; Postacchini V; Ricotti G; Rosa L; Simonacci M; Offidani A G Ital Dermatol Venereol; 2018 Feb; 153(1):5-10. PubMed ID: 27845513 [TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]